Ultrasensitive immunoassay technology drives blood-based biomarkers for Alzheimer’s disease
Leveraging Quanterix’s Simoa® platform, researchers lay the groundwork for pre-symptomatic Alzheimer’s diagnosis, guided treatment, and accelerated clinical drug trials
Select Science | October 3, 2023
Quanterix’s ultrasensitive digital immunoassay technology, Single molecule array (Simoa®), is helping researchers uncover novel blood-based biomarkers for Alzheimer’s disease (AD) and explore their value in clinical trials, drug development, and patient care.
We spoke with Dr. Nicholas Ashton, Associate Professor of Neurochemistry at the University of Gothenburg, and Dr. Milena Milutinovic, Senior Manager of Field Applications at Quanterix, to learn more about the evolving landscape of AD diagnosis and treatment, the capabilities of the Simoa® platform, and the impact blood-based biomarkers could have on the early detection and management of AD and other neurological disorders.
Share this page